Ridgefield, Conn., July 13, 2023 –Boehringer Ingelheim announced today that Cyltezo®(adalimumab-adbm) injection, a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira®(adalimumab), has been added to Express Scripts’ National Preferred Formulary. Cyltezo is...
16EXPRESSSCRIPTS2012WORKERS’COMPENSATIONDRUGTRENDREPORT I N T R O D U C T I O N ANTICONVULSANTS Medicationsinthisclassareusedmainlytocontrolseizures.However,somesuchasLyrica®TopFiveAnticonvulsantsby2012MarketShare ® (pregabalin)andNeurontin(gabapentin)areeffectiveforcontrollingneuropathicpain. ...